[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
US STOCK MARKET - HTDS Medical Research---CANCER Trials.....Dillan
US STOCK MARKET - HTDS Medical Research---CANCER Trials.....Dillan
Wed, 03 Dec 2003 00:35:58 +0200
US Stock Market - Stock Profile of the Week
Sector: MEDICAL RESEARCH
BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS
Before we begin our profile we have very exciting, breaking news...
Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials
BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases
Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the
toxicity tests required to proceed to the live cancer trials. Testing Tubercin®
on live Melanoma, Lung and Breast cancer cells will begin immediately. The
President and CEO, Mr. Colm J. King, met with the spokesperson of the medical
group at their offices in Oklahoma City. Mr. King was advised that the tests
were conducted under strict FDA (Federal Drug Administration) guidelines. Full
test results will be available at the corporate offices as soon as the reports
and findings are printed.
"These are the most promising results to date regarding Tubercin® and we're
looking forward to additional positive results in the near future," stated Mr.
King. "These tests prove that Tubercin® is non-toxic and is the first step on
the way to human clinical trials as well as the first positive breakthrough
conducted in the United States with an independent medical group for Tubercin®."
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated
("HTTD") holds the international marketing rights, except South Korea, to
Tubercin®, a patented immunostimulant developed for combating Cancer under
medical patent (US Patent 6,274,356). The unique properties unlike other cancer
products are clearly stated in the abstract summary of the patent... "A
carbohydrate complex, which is a mixture of low molecular-weight
polysaccharides of an arabinomannan structure extracted from Mycobacterium
tuberculosis, is highly effective in treating various cancer patients without
incurring any adverse side effects."
STOCK PROFILE OF THE WEEK
HTDS is now at an emerging and potentially explosive stage. As stated in their
press release, Tubercin is now ready to proceed (after tests conducted under
strict FDA guidelines) to human clinical trials. While they have jumped one
very big hurdle, they are still in the early stages of development and now is a
great time for investors to take heed.
Over the past ten years, epoch making anticancer agents have continuously been
introduced, but the mortality of cancer patients have been rising in the U.S.
and the European countries not to mention Japan and Korea. The decisive measure
to cope with cancer is surgery.
When the cancer cells spread throughout the body instead of remaining on the
original spot, the treatment should take into consideration chemotherapy,
radiation therapy and immunotherapy. The drawback of such therapies, however,
is they incur damages not only on cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened
patients, especially those above 70. Historically, various forms of
immunotherapy have been performed, falling short of therapeutic expectation.
When Bacille calmetteguerin is used as an active no-specific immunotherapeutic
agent, however, the patient's prognosis turns better through a simulative
action on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from
microbacterium tuberculosis to be used as immunostimulant. This was meant to
activate the T-lymphocyte of the cancer patient to produce lymphokine. This
process strengthened and promoted immuno surveillance activities in deficient
state and alleviated the pain and prolonged the life of cancer patients.
Of late the pharmaceutical industry in advanced countries started to put on the
market so called cancer vaccines (active specific immunotherapy). The vaccines,
bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells
to generate antibodies to cancer cells, facilitating the killer T-cells to
recognize and destroy cancer cells.
The laboratory work to modify autologous or allogenic cancer cells are not
ordinary and simple. When our lab work augments the active specific
immunotherapeutic agents, the Tubercin will be one of the best adjuvants.
Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin
helps maintain healthy T-cells. Consequently, we focus our effort on the
application of Tubercin to AIDS.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant,
TUBERCIN strengthens the human body's own immune system and assists the body in
seeking out and combating cancer cells. HTTD is potentially able to develop
TUBERCIN into a low-cost product to treat cancer patients on an international
scale. Salient treatment, through the administration of TUBERCIN, could
positively affect thousands of lives in North America. In addition, Europe and
Asia have millions of lives at risk each year because of viral diseases such as
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been
administered to human patients in stages three and four of terminal cancer.
There have been no indications of any adverse side effects in human trials
There has been encouraging results of patients with TUBERCIN in the last
fourteen years. Various forms of cancer were involved and many of the patients
A review of clinical studies indicate TUBERCIN has no side effects and could
possibly be administered in conjunction with other such modalities for the
treatment of cancer without any adverse effects. The scientific presumption
would be the distinct possibility of a strengthened immunity system and the
administration of treatment such as chemotherapy at the later stages of tumor
growth would not be impeded by the weakened condition of the terminal cancer
patient. To this end the Company has been assisted by outside consultants
reviewing the research data and human trials involving TUBERCIN to see
specifically whereby incidents of dual treatment produced favorable results in
terms of moving toward indication of prolongation of the life of the cancer
There is recognition that morphine is an trusted pain killer, but in totality
it cannot be said that it has no side effects. In the maintaining of patient
care, there is the strong possibility that TUBERCIN could be also considered as
a candidate for a pain management. The Company's scientists describe TUBERCIN
as having the high propensity of deadening the nerve endings in specific areas
of the body where cancer has caused erosion and consequently much pain.
Presently, HTTD has the patent rights for Korea, Japan and the United States.
The Korean patent was issued on October 29, 1998 (Registration No. 173362). The
Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The
United States patent was issued on August 14, 2001 (Registration No.6,274,356).
Currently, patents are pending for Canada and Europe (the United Kingdom,
France, Germany, Italy and Spain).
CANCER IN OUR TIME
In the 20th century, the number of cancer patients has been on the increase.
Although many anti-cancer agents were developed and an enormous study on its
essence continued, the mortality by cancer still is increasing. Mankind may be
chronically threatened with cancer in the 21st century. Nine million new case
of cancer occur annually and five million people die from breast cancer,
reports the World Health Organization. Dramatic increases in life expectancy
and change in lifestyle are estimated to increase the number of new cancer
cases to 20 million annually by 2020 and cancer deaths to more than 10 million.
About 552,200 Americans - more than 1,500 people a day - are excepted to die of
cancer this year. In the United States, one of every four deaths is attributed
to cancer. Cancer is the second-leading cause of death in the United States.
Exceeded only by heart disease. About 5 million lives have been lost to cancer
since 1990 and about 13 million new cases have been diagnosed. In 2000, more
then 1.2 million new cancer cases are expected to be diagnosed. The number of
cancer cases will continue to grow, spurred by the aging population. By 2009,
this patient group could total 8.4 million. In 1997, about 6.3 million people
worldwide died from some form of cancer, and most major international cancer
agencies expect this number to double by 2022.
Please note that HTDS had absolutley nothing to do with this report and is not
a participant in any way.
No more advertisements: http://doubleopt.biz/optout.html
Stock Market Today is an independent research firm. This report is based on
Stock Market Today's independent analysis but also relies on information
supplied by sources believed to be reliable. This report may not be the opinion
of HTDS management. Stock Market Today has also been retained to research and
issue reports on HTDS. Stock Market Today may from time to time purchase or
sell HTDS common shares in the open market without notice. The information
contained in this report shall not constitute, an offer to sell or solicitation
of any offer to purchase any security. It is intended for information only.
Some statements may contain so-called "forward-looking statements". Many
factors could cause actual results to differ. Investors should consult with
their Investment Advisor concerning HTDS. Copyright 2003 © Stock Market Today
Ltd. All Rights Reserved. This newsletter was distributed by MMS, Inc. MMS was
paid eight hundred and fifty thousand shares HTDS stock to distribute this
report. MMS is not affiiated with Stock Market Today and is not responsible for
eno gjyb es vrzurs nxerrd c toryawnff j
xo je u ilrr zwn u r
|[Prev in Thread]
||[Next in Thread]|
- US STOCK MARKET - HTDS Medical Research---CANCER Trials.....Dillan,
Josefa Marsh <=